ARCHIVES

ODAC Recommends Femara Campath For FDA Approval.

This article is from The Cancer Letter archive.

Vol. 27 No. 01 | January 5, 2001

Download PDF Visit The Full Archive

Related Articles

Pancreatic Cancer Treatment Shows Postive Early Results

December 30, 2005

ODAC Votes 10-0 In Favor Of Avastin For Recurrent Glioblastoma Multiforme

April 3, 2009

Revised Price Equivalent to Lower Dose of Avastin

November 8, 2012

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992

FDA Advisors Recommend Use of Cytokines GM-CSF, G-CSF In BMT And Chemotherapy

January 4, 1991

NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.

April 20, 2007